Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 621 to 630 of 2649 total matches.
Intra-Articular Injections for Osteoarthritis of the Knee
The Medical Letter on Drugs and Therapeutics • Mar 27, 2006 (Issue 1231)
for painful osteoarthritis
(OA) of the knee, have been at least somewhat discredited,
1
some patients ...
Now that glucosamine and chondroitin, 2 favorite over-the-counter remedies for painful osteoarthritis (OA) of the knee, have been at least somewhat discredited, some patients will be asking about alternatives. One of these is periodic intra-articular injection of a corticosteroid or hyaluronic acid preparation.
Phexxi - A Nonhormonal Contraceptive Gel
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
), but
was never marketed.1
Phexxi — A Nonhormonal
Contraceptive Gel
CHOICE OF CONTRACEPTIVES — Intrauterine ...
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
Prenatal Acetaminophen Use and Autism
The Medical Letter on Drugs and Therapeutics • Dec 08, 2025 (Issue 1743)
-term neurological effects such as autism
in their children.1 The announcement cites a
“consensus ...
Acetaminophen has been considered the drug
of choice for treatment of fever and pain during
pregnancy for decades, but a recent announcement
by the US Department of Health and Human Services
(HHS) has prompted discussion about its effects on
fetal neurodevelopment and the risk of autism.
Med Lett Drugs Ther. 2025 Dec 8;67(1743):193-5 doi:10.58347/tml.2025.1743a | Show Introduction Hide Introduction
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
insomnia
...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10 doi:10.58347/tml.2023.1667b | Show Introduction Hide Introduction
Desogestrel - A New Progestin for Oral Contraception
The Medical Letter on Drugs and Therapeutics • Aug 06, 1993 (Issue 902)
CONTRACEPTIVES
1
Estrogen (µg) µg per mg per
Drug (ethinyl estradiol) month Progestin (mg)
2
month Cost
3 ...
Desogen (Organon) and Ortho-Cept (Ortho), two oral contraceptives each containing a low dose (30 mcg) of the estrogen ethinyl estradiol plus 150 mcg of the progestin desogestrel, were recently approved by the US Food and Drug Administration for marketing in the USA. They are the first US oral contraceptives to contain desogestrel, which is widely used in oral contraceptive combination products in other countries. Desogestrel is one of three new progestins (norgestimate and gestodene are the others) considered less androgenic than previously available progestins (L Speroff et al, Obstet...
A New Testosterone Gel (Fortesta) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011 (Issue 1362)
as a Schedule III
controlled substance. Table 1 lists some available
testosterone products, including 2 ...
The FDA has approved Fortesta (Endo), a topical gel,
for testosterone replacement therapy in adult males
with hypogonadism. It is classified as a Schedule III
controlled substance. Table 1 lists some available
testosterone products, including 2 other gels.
Casirivimab and Imdevimab (REGEN-COV) for Post-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
significantly less often in patients who received the
antibodies than in those who received placebo (1.5%
vs ...
The investigational monoclonal antibodies casirivimab
and imdevimab (REGEN-COV – Regeneron) have
been available in the US under an Emergency Use
Authorization (EUA) since late 2020 for use together
to treat mild to moderate COVID-19 in persons ≥12
years old who weigh ≥40 kg and are at high risk of
progression to severe disease or hospitalization. The
FDA has now expanded this EUA to allow use of the
antibodies together for post-exposure prophylaxis
of COVID-19 in such persons, if they are not fully
vaccinated against COVID-19 or are unlikely to have
an adequate immune response...
Tafenoquine (Arakoda; Krintafel) for Malaria
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
: ta fen’ oh kwin Arakoda: air’ uh koh’ duh
Krintafel: krin tah fell
Table 1. Primaquine ...
The oral antimalarial tafenoquine succinate, a long-acting
analog of primaquine, has been approved by
the FDA in 2 different strengths. Arakoda (100-mg
tablets; Sixty Degrees) is indicated for the prophylaxis
of malaria in adults. Krintafel (150-mg tablets; GSK) is
indicated for the prevention of relapse (radical cure)
of Plasmodium vivax malaria in patients ≥16 years old
undergoing treatment for acute P. vivax infection.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
.............................................................................. p 1
CHA2DS2-VASc Scoring ............................................................. p 2
Oral ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
In Brief: Absorica for Acne
The Medical Letter on Drugs and Therapeutics • Jan 21, 2013 (Issue 1408)
available for treatment of acne.1
The FDA has recently approved a new oral isotretinoin
product (Absorica ...
The oral retinoid isotretinoin (Accutane, and others) is the most effective drug available for treatment of acne.1 The FDA has recently approved a new oral isotretinoin product (Absorica – Cipher/Ranbaxy) for treatment of severe, recalcitrant nodular acne.Isotretinoin can completely clear severe nodulocystic lesions, in some cases leading to remission that can persist for years after treatment is stopped. Mucocutaneous adverse effects include dry skin, dry eye, epistaxis, nasopharyngitis, cheilitis, alopecia, eczema, skin fragility and photosensitivity. Musculoskeletal symptoms,...
